scispace - formally typeset
M

Michael J. Edwards

Researcher at University of Cincinnati

Publications -  327
Citations -  15212

Michael J. Edwards is an academic researcher from University of Cincinnati. The author has contributed to research in topics: Sentinel lymph node & Breast cancer. The author has an hindex of 61, co-authored 316 publications receiving 13936 citations. Previous affiliations of Michael J. Edwards include University of L'Aquila & University of Arkansas at Little Rock.

Papers
More filters
Journal ArticleDOI

Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used.

TL;DR: In multi-institutional practice, sentinel lymph node biopsy using dual-agent injection provides optimal sensitivity for detection of nodal metastases and indicates that this procedure is a suitable alternative to routine axillary dissection across a wide spectrum of surgical practice and hospital environments.
Journal ArticleDOI

Chemokine involvement in hepatic ischemia/reperfusion injury in mice: Roles for macrophage inflammatory protein‐2 and kupffer cells

TL;DR: The data suggest that the local expression of MIP‐2 and KC are important mediators involved in neutrophil‐dependent hepatic injury induced by ischemia and reperfusion in mice.
Journal ArticleDOI

Updated Recommendations for Control of Surgical Site Infections

TL;DR: It is suggested that uniform adherence to the proposed guidelines for the prevention of surgical infections could reduce wound infections significantly; namely to a target of less than 0.5% in clean wounds, less than 1% inclean contaminated wounds and less than 2% in highly contaminated wounds, and decrease related costs to less than one-half of the current amount.
Journal ArticleDOI

Sentinel-Lymph-Node Biopsy for Breast Cancer — Not Yet the Standard of Care

TL;DR: Sentinel-lymph-node biopsy has become a standard technique for determining the nodal stage of disease in patients with melanoma and is suggested to be a viable option for breast cancer patients.